Hathal Haddad, Head of Interventional Radiotherapy Unit at the Department of Radiation Oncology at University Hospital Tübingen, shared a post on LinkedIn:
“New Series: Increasing Awareness of Interventional – Radiotherapy (Brachytherapy)
Episode 3: Salvage Brachytherapy for Recurrent Prostate Cancer
When prostate cancer returns after radiotherapy, many patients fear that treatment options are limited.
The good news? Modern Salvage Brachytherapy offers a second chance for cure.
- The RESPRO multicenter study, including 188 patients, demonstrated:
- 65% biochemical control at 5 years
- 72% clinical relapse-free survival at 5 years
- 98% overall survival at 5 years
- Excellent long-term outcomes up to 10 years
- Very low rates of severe toxicity
Perhaps the most important message:
- Highly effective
- Organ-preserving
- Minimally invasive
- Low toxicity
- A true precision treatment
As imaging technologies such as PSMA PET/CT continue to improve, we can detect recurrence earlier and select patients more accurately, making salvage treatment even more successful.
For many patients, recurrence does not mean the end of curative treatment. With modern Interventional Radiotherapy, it can be the beginning of a new opportunity.
Let’s continue spreading awareness that Brachytherapy is not only a primary treatment—it is also one of the most powerful salvage treatments available for selected patients with recurrent prostate cancer.
Precision. Preservation. Hope.
Article: Salvage brachytherapy for local recurrence of prostate cancer. Evaluation of technique and dose fractionation, impact of early diagnosis, and its effect on survival. A multicenter retrospective observational study: RESPRO
Authors: Patricia Willisch, Elena Villafranca, Susana Roldan Ortega, Silvia Rodriguez Villalba, Alai Goñi, Juan Adrian Camus, Luis Sopeña Sanz, Ana Alonso García, Teresa Muñoz Miguelañez, Saul Lopez-Soliño, Beatriz Vázquez-Barreiro, David Büchser
Other articles featuring Hathal Haddad on OncoDaily.
